CytomX breast cancer Phase 2 misses marks

  Study meets primary endpoint of objective response rate in HR+/HER2-non-amplified breast cancer -

- Secondary endpoints including clinical benefit rate at 24 weeks and median progression-free survival were 40 percent and 2.6 months, respectively -

- Arm B did not pass protocol-defined futility boundary in triple-negative breast cancer; enrollment to Arms B and C to be discontinued -

- Company to host conference call and webcast today at 5:00 pm ET / 2:00 pm PT 

CytomX management will host a conference call and a simultaneous webcast today at 5:00 pm ET (2:00 pm PT) to discuss these results. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. A live webcast of the call can be accessed via the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations.

https://finance.yahoo.com/news/cytomx-therapeutics-announces-phase-2-200500633.html